RESUMO
Seventy-eight patients with tinea corporis or tinea cruris participated in a double-blind study with either 100 mg itraconazole or 500 mg ultramicronized griseofulvin for 15 consecutive days. Clinical outcome was significantly in favor of itraconazole at completion of treatment (72% response rate vs. 51%) and at the follow-up visit (91% response vs. 64%). The most important difference between both treatments was the mycologic outcome, for which itraconazole showed a cure rate of 87% compared to 57% for griseofulvin 2 weeks after completion of therapy. It is suggested that 100 mg of itraconazole orally once daily is significantly more effective than 500 mg of griseofulvin once daily for 15 days in the treatment of glabrous skin infections. Both drugs were well tolerated.
Assuntos
Antifúngicos/uso terapêutico , Griseofulvina/uso terapêutico , Cetoconazol/análogos & derivados , Tinha/tratamento farmacológico , Adolescente , Adulto , Idoso , Criança , Ensaios Clínicos como Assunto , Método Duplo-Cego , Feminino , Humanos , Itraconazol , Cetoconazol/uso terapêutico , Masculino , Pessoa de Meia-Idade , Distribuição AleatóriaRESUMO
Oxatomide was evaluated in a double-blind study of 35 patients with chronic urticaria. For 5 weeks patients received at random either 30 mg oxatomide b.i.d. or a placebo. Oxatomide significantly reduced not only the duration of the attacks but also the severity of erythema, lesions and itching. This lower level of suffering was clearly reflected by a diminished need for additional antiallergic medication. The overall response to treatment was rated excellent or good in 72% of the oxatomide-treated patients against only 23% of the controls which is a significant difference. Sleepiness was reported in 1 patient of each group.
Assuntos
Piperazinas/uso terapêutico , Urticária/tratamento farmacológico , Adolescente , Adulto , Doença Crônica , Ensaios Clínicos como Assunto , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , PlacebosAssuntos
Antifúngicos/uso terapêutico , Dermatomicoses/tratamento farmacológico , Imidazóis/uso terapêutico , Onicomicose/tratamento farmacológico , Piperazinas/uso terapêutico , Adolescente , Adulto , Idoso , Fenômenos Químicos , Química , Criança , Pré-Escolar , Ensaios Clínicos como Assunto , Dermatomicoses/etiologia , Feminino , Humanos , Cetoconazol , Masculino , Pessoa de Meia-Idade , Onicomicose/etiologiaRESUMO
59 outpatients (27-82 years) with a chronic leg ulcer participated in a 20-week double-blind placebo-controlled trial of levamisole (levamisole 30; placebo 29). They were instructed to take a body weight adjusted number of tablets (2-5) for two consecutive days every week. Previously used topical treatment was kept unchanged. Control examinations were done every two weeks. Double-blind treatment was stopped because of evident failure after a median duration of 8 weeks in 2 levamisole and 8 placebo patients. The percentage of cured patients became significantly superior in the levamisole group from week 8 onwards, so that, by the end of the study, all levamisole patients were cured against only 76% of the controls. Three levamisole patients reported moderate gastric complaints.
Assuntos
Úlcera da Perna/tratamento farmacológico , Levamisol/uso terapêutico , Adulto , Idoso , Ensaios Clínicos como Assunto , Método Duplo-Cego , Feminino , Humanos , Levamisol/administração & dosagem , Levamisol/efeitos adversos , Masculino , Pessoa de Meia-Idade , Placebos , Fatores de TempoRESUMO
In a 4-week double-blind trial, Daktacort cream was compared with each of its constituents (i.e. miconazole 2% and hydrocortisone 1%) in a total of 63 patients (aged 12-60 years) with inflamed skin infections of bacterial or mycotic origin. Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation. This tendency persisted throughout the trial but at the end miconazole treatment proved also superior to hydrocortisone.
